You are here: Industry Insights > CAM2038

News List

Buvidal Weekly and Buvidal Monthly (CAM2038) approved in Australia as the first long-acting treatment of opioid dependence firstwordpharma
November 29, 2018
Camurus announced today that the Australian Therapeutic Goods Administration (TGA) has approved the company's lead products Buvidal® Weekly and Buvidal® Monthly (CAM2038) for maintenance treatment of opioid dependence within a framework of medical, social
received approval pharmafile
November 28, 2018
Europe has seen its first and only approval of a long-acting therapy for opioid dependence, as the European Commission (EC) confirms the marketing authorisation of Camurus’ Buvidal (CAM2038).
Braeburn Announces Positive Top-line Phase 3 Results for CAM2038 americanpharmaceuticalreview
September 20, 2018
Braeburn announces positive top-line results for a Phase 3 study of CAM2038 for the treatment of moderate-to-severe Chronic Low Back Pain (CLBP) in patients previously on long-term daily opioid therapy. CAM2038 is an investigational buprenorphine weekly a
Braeburn Resubmits New Drug Application for CAM2038 for Opioid Use Disorder drugs
June 12, 2018
Braeburn announces the resubmission of the New Drug Application (NDA) for CAM2038, an investigational buprenorphine flexible-dose weekly and monthly depot injection for the treatment of opioid use disorder (OUD).
Braeburn Resubmits New Drug Application for CAM2038 for Opioid Use Disorder drugs
May 31, 2018
Braeburn announces the resubmission of the New Drug Application (NDA) for CAM2038, an investigational buprenorphine flexible-dose weekly and monthly depot injection for the treatment of opioid use disorder (OUD).